Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes

International Journal of Artificial Organs

Volumn 22, Issue 7, 1999, Pages 505-510

  Fujioka, H ^a   Eguchi, S ^a   Sugiyama, N ^a   Kawazoe, Y ^a   Kawashita, Y ^a   Kamohara, Y ^a   Azuma, T ^a   Furui, J ^a   Kanematsu, T ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bioartificial liver; Human hepatic failure plasma; Porcine hepatocyte

Indexed keywords

AMINO ACIDS; PLASMA (HUMAN);

ALANINE AMINOTRANSFERASE; BIOARTIFICIAL LIVER; CONTROL GROUPS; HEPATOCYTES; HUMAN HEPATIC FAILURE PLASMA; HUMAN PLASMAS; PERFORMANCE; PORCINE HEPATOCYTE; PROTEASE INHIBITOR; THROMBIN TIME;

ARTIFICIAL ORGANS;

ALANINE AMINOTRANSFERASE; NAFAMSTAT MESILATE;

ARTICLE; ARTIFICIAL LIVER; CELL VIABILITY; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LIVER CELL; LIVER FAILURE; NONHUMAN; PLASMA; PROTEINASE INHIBITION; SWINE;

EID: 0032834514     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889902200709     Document Type: Article

References (29)

1. Vacanti JP. Beyond transplantation: Third annual Samuel Jason Mixter Lecture. Archiv Surg 1988; 123: 545-9.
2. Hoofnagle J, Carithers RL, Jr., Shapiro C, Ascher N. Fuliminant hepatic failure: summary of a workshop. Hepatology 1995; 21: 240-52.
3. Kasai S, Sawa M, Mito M. Is artificial liver clinically available? A historic review of biological artificial liver support systems. Artif Organs 1994; 18: 348-54.
4. Neuzil DF, Rozga J, Moscioni AD, et al. Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surgery 1993; 113:340-3.
5. Rozga J, Podesta L, Le Page E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994; 219: 538-46.
6. Sussman NL, Gislason GT, Conlin CA, et al. The hepatic extracorporeal liver assist device: initial clinical experience. Artif Organs 1994; 18: 390-6.
7. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993; 17: 258-65.
8. Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. Ann Surg 1997; 225: 484 - 94.
9. Dalmasso AP, Vercellotti GM, Platt JL, et al. Inhibition of complement-mediated endothelial cell toxicity by decayaccelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52:530-3.
10. Terajima H, Shirakata Y, Yagi T, et al. Successful long-term xenoperfusion of the pig liver. Transplantation 1997; 63: 507-12.
11. Tuso PJ, Cramer DV, Yasunaga C, Cosenza C, Wu G-D, Makowka L Removal of natural human xenoantibodies to pig vascular endothelium by perfusion of blood through pig kidneys and livers. Transplantation 1993; 55:1375.
12. Fujii S, Hitomi Y. New synthetic inhibitor of Cr1, C1s elastase, thrombin, plasma, kallikrein and trypsin. Biochem Biophys Acta 1981; 661: 342-5.
13. Manabe T, Hirano T, Imanishi K, Ando K, Yotsumoto F, Tobe T. Protective effect of Nafamostat Mesilate on cellular and lysosomal fragility of acinar cells in rat cerulein pancreatitis. Int J Pane 1992; 12:167-72.
14. Uchiba M, Okajima K, Abe H, Okabe H, Takatsuki K. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue-factor Ylla comlex activity. Thromb Res 1994; 74: 155-61.
15. 2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepato-Gastroenterol 1992; 39:59-61.
16. Miyagawa S, Shirakura R, Matsumiya G, et al. Prolonging discordance xenograft survival with anticomplement reagents . K76COOH and FUT-175. Transplantation 1993; 55:709-13.
17. Issekutz AC, Roland DM, Patrick RA. The effect of FUT-175 (Nafamostat Mesilate) on C3a, C4a, and C5a generation in vitro and inflammatory reactions in vivo. Int J Immunopharmacol 1990; 12:1-9.
18. Clavien PA, Sanabria JR, Upadhaya A, Harvey PR, Strasberg SM. Evidence of the existence of a soluble mediator of cold preservation injury. Transplantation 1993; 56: 44-53.
19. Nagaya M, Futamura M, Kalo J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemmorhagic complications during extracorporeal membrane oxygenation - a preliminary report. J Pediat Surg 1997;32:531-5.
20. Kawazoe Y, Eguchi S, Sugiyama N, et al. Protective effect of Nafamostat Mesilate on injury of porcine hepatocytes in human plasma. Cell Transplant (in press).
21. Berry MM, Friend DS. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and structural study. J Cell Biol 1969; 43: 506-20.
22. Seglen PO. Preparation of rat liver cells. Exp Cell Res 1974; 74: 450-4.
23. Nakamura T, Asano O, Ichihara K, Ichihara A. Increased survival of rat hepatocytes in serum-free medium by inhibition of a trypsin-like protease associated with the plasma membranes.'Exp Cell Res 1984; 154:81-91.
24. Tanaka K, Nakamura T, Ichihara A. A unique trypsin-like protease associated with plasma membrane of rat liver. Purification and characterization. Biol Chem 1986; 261: 2610-15.
25. Ikari N, Sasaki Y, Hitomi Y, Fujii S. New synthetic inhibitor to the alternative complement pathway. Immunology 1983; 49: 685-91.
26. Okada S, Sato K, Ichiki K, et al. Does protease inhibitor inhibit complement activation caused by the immune complex associated with cell surface antibody? J Int Med Res 1991; 234-6.
27. Kawauchi M, Takeda M, Nakajima J, Matsumoto J, Furuse A. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and Nafamostat Mesilate. Transplant Proc 1994;26:1076-7.
28. Ohta K, Tanaka N, Orita K. Discordant liver xenograft transplantation. Transplant Proc 1994; 26: 2435-8.
29. Takahashi M, Ishikura H, Takahashi C, et al. Immunologie considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. ASAIO J 1993; 39: M242-6.